Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Feb 20, 2025
Emerging Company Profile

Switch: Precision siRNA knockdown

San Francisco-based biotech is pursuing CNS diseases with three-stranded siRNAs that can target specific cell types within a tissue
BioCentury | Oct 22, 2024
Product Development

Newco trend watch: Clusters of launches point to areas undergoing derisking

Oligo delivery to the kidney, and two emerging use cases for T cell engagers, each get newcos; most with mega-
BioCentury | Oct 15, 2024
Emerging Company Profile

Commit: Activating the complement pathway to deeply deplete target cells

Launched in May, Danish company’s tech engages C1q to trigger complement-induced killing of cancer or autoimmune cells
BioCentury | Jun 7, 2024
Finance

Public Equity Report: Rapport posts healthy first-day gain as Telix, Grail head for NASDAQ

Plus: Structure, Annexon and Summit follow clinical readouts by raising money
BioCentury | Jun 4, 2024
Product Development

Clinical Report: Obesity win for Structure, plus upbeat data for Annexon, Agios, Arrowhead, Ultragenyx, Intellia

Away from ASCO, handful of biotechs eye follow-ons or regularly submissions backed by new data
BioCentury | May 26, 2023
Finance

May 25 Quick Takes: VarmX is latest biotech to extend series B

Plus: Apellis/Sobi candidate misses in ALS and updates from Annexon, Pfizer and more
BioCentury | Oct 19, 2022
Data Byte

The evolving geographic atrophy pipeline

Roche drops galegenimab and NGM data disappoint, as regulatory milestones approach for Apellis, Iveric 
BioCentury | Mar 4, 2022
Distillery Therapeutics

mAb against host transferrin receptor for Junín virus

BioCentury | Jan 7, 2022
Distillery Therapeutics

C1QTNF3 identified as target in tendinopathy

BioCentury | Oct 27, 2021
Distillery Therapeutics

Inhibiting complement for chronic MS lesions

Items per page:
1 - 10 of 45
Help Center
Username
Request a Demo
Request Training
Ask a Question